Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial
Summary
CONCLUSIONS The updated analysis of the phase 3 PHILA trial confirmed the superiority of pyrotinib in combination with trastuzumab and docetaxel over placebo in combination with trastuzumab and docetaxel in sustaining longer progression-free survival and improving overall survival for initial treatment of HER2 positive metastatic breast cancer. The safety profile remained consistent with interim findings, with no new safety signals identified during extended follow-up. This analysis reinf
Content
# Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial
*Published: 2026 Mar 16*
## CONCLUSIONS
The updated analysis of the phase 3 PHILA trial confirmed the
superiority of pyrotinib in combination with trastuzumab and docetaxel over
placebo in combination with trastuzumab and docetaxel in sustaining longer
progression-free survival and improving overall survival for initial treatment
of HER2 positive metastatic breast cancer. The safety profile remained
consistent with interim findings, with no new safety signals identified during
extended follow-up. This analysis reinforces the efficacy of this dual anti-HER2
(pyrotinib plus trastuzumab) regimen as an effective treatment strategy for this
patient population.
## TRIAL REGISTRATION
ClinicalTrials.gov NCT03863223.
DOI: 10.1136/bmj-2025-087259